Jfl Life Sciences Limited
Incorporated in 2010, JFL Life Sciences Limited manufactures pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam) solid oral dosage forms tablets and capsules (general) Solid Oral Dosage forms, and Oral rehydration solutions (ORS).
What Jfl files
- Others44
- Board Meeting17
- Important14
- Updates8
- Dividend/Bonus3
- Results1
JFL Life Sciences approved financial results for the quarter and financial year ending March 31, 2026. Revenue from operations hit 63.09 Cr (Q4) and 131.36 Cr (FY). Net profit reached 1.66 Cr (Q4) and 6.40 Cr (FY). The board also appointed a new Internal Auditor.
JFL Life Sciences' Board approved a 1:1 Rights Issue of ~3.30 Cr new shares at Rs. 10 each, raising ~Rs. 33 Cr. This effectively doubles outstanding shares, providing existing investors an opportunity to subscribe.
JFL Life Sciences approved Q1 FY26 financial results: Revenue at Rs 11.59 Cr, Net Profit at Rs 0.75 Cr. Ms. Khyati Shah was appointed as an Independent Director. MD's remuneration was also increased to Rs 0.24 Cr p.a., pending shareholder approval.
JFL Life Sciences confirmed an update on the appointment of Ms. Amita Pragada as an Additional Non-executive Independent Director. The company affirmed that Ms. Pragada is not debarred from holding a directorship by any regulatory authority. This statement provides assurance regarding the eligibility of the recently appointed independent director, fulfilling...
JFL Life Sciences has secured a domestic supply order from Brihanmumbai Municipal Corporation for injections and sera vaccines worth ₹11.95 Cr (including taxes). The contract spans two years, from mid-2025 to mid-2027, with no promoter or related party involvement on the awarding side. This order strengthens JFL’s presence in public...